Euro-celtique S.a.

Purdue Pharma L.p.

Rhodes Pharmaceuticals L.p.

Mundipharma Laboratories Gmbh

Derek Allan Prater

Stewart Thomas Leslie

Ronald Brown Miller

Sandra Therese Malkowska

Trevor John Knott

Malcolm Walden

Kevin John Smith

Hassan Mohammad

Joanne Heafield

Ian R Buxton

Benjamin Oshlack

Curtis Wright

Alexander Oksche

Sandra Therese Antoinette Malkowska

Richard S Sackler

Walter Wimmer

Udo Hahn

Horst Winkler

William Heath

Timothy Holden

Deborah Challis

Harjit Tamber

Adrian Brown

Helen Critchley

Geoffrey Gerard Hayes

Steve Whitelock

Treavor John Knott

Philip J Neale

Christof Spitzley

Helen Kathleen Danagher

Allan John Miller

Vincenzo Martinelli

Gerhard Josef Heun

Bernard Kennedy

Vanessa Addison

Hasssan Mohammad

Alison A Norman

Deborah L Singh

Mohammed Hassan

Christian Leuner

Christopher Robert Bland

Hassan Mohammed

Geoff Hayes

Will Heath

Alexander Schuetz

Alexander SCHÜTZ

Stuart Thomas Leslie

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.

Oxycodone formulations

Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.

Delayed release pharmaceutical formulations

The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.

Buprenorphine-wafer for drug substitution therapy

The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.

Opioid composition for treating skin lesions

Once-A day oxycodone formulations

Once-a-day oxycodone formulations

The invention relates to a process for preparing a controlled release pharmaceutical extrudate using a melt extruder,

Extrusion

A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are preferably made by melt extrusion, and can have rubbery characteristics and can exhibit tamper resistance.

Particulates

A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.

Pharmaceutical formulation

A stool softener and enteric coated bisacodyl form of a pharmaceutical composition.

Pharmaceutical composition

Growing community of inventors

Cambridge, United Kingdom

Derek Allan Prater